Fusiones y adquisiciones (M&A)Salud - Farma - Biotecnología
EXOR TO RAISE ITS STAKE IN BIOMÉRIEUX
19/11/2026 07:59
AMFPublicación inmediata
Exor N.V. (“Exor”) and Institut Mérieux today announce that Exor will increase its direct stake in bioMérieux, a world leader in the field of in vitro diagnostics, from 3.87% to 8.53%, reflecting its confidence in the company.
Investor Relations Exor
Tel. +31 (0)20 240 2 222 ir@exor.com
Media Exor
Tel. +31 (0)20 240 2 221 media@exor.com
Media Institut Mérieux
Tel. : +33 (0)4 78 87 70 70 communication@institut-merieux.com
Investor Relations bioMérieux
Tel. +33 (0)4 78 87 20 00 investor.relations@biomerieux.com
Media bioMérieux
Tel. +33 (0)4 78 87 20 00 media@biomerieux.com
Amsterdam and Lyon, 19 November 2026
EXOR TO RAISE ITS STAKE IN BIOMÉRIEUX
- Exor becomes a long-term investor in bioMérieux
- Institut Mérieux remains firmly committed to bioMérieux as its majority shareholder
- Exor maintains a significant shareholding in Institut Mérieux, continuing the relationship established in 2022
Exor N.V. (“Exor”) and Institut Mérieux today announce that Exor will increase its direct stake in bioMérieux, a world leader in the field of in vitro diagnostics, from 3.87% to 8.53%, reflecting its confidence in the company.
Exor will receive the bioMérieux shares through a reduction of Institut Mérieux’s share capital, in exchange for part of its Institut Mérieux shares.
Following completion, which is expected in December 2026, subject to the creditor objection period and formal approval by Institut Mérieux’s shareholders, Exor will hold 8.53% of bioMérieux’s share capital and 5.35% of its voting rights. Institut Mérieux will remain bioMérieux’s majority shareholder, with 55.24% of the share capital and 68.67% of the voting rights. After the transaction, Exor will hold 5.02% of Institut Mérieux’s share capital and 2.58% of its voting rights.
Exor has been a shareholder of Institut Mérieux since 2022 and a direct shareholder of bioMérieux since 2025. bioMérieux’s Board of Directors is expected to propose the appointment of Benoît Ribadeau-Dumas as Exor’s representative at its next Annual General Meeting. He is already a board member of Institut Mérieux and a non-voting observer on bioMérieux’s Board. Institut Mérieux’s governance will be unchanged.
Exor and the Mérieux family do not intend to act in concert with respect to bioMérieux. Alexandre Mérieux, Vice-Chairman of the Board of Directors of Institut Mérieux and Chairman of the Board of Directors of bioMérieux, said: “Over the years, we have developed a strong relationship with Exor built on trust, close dialogue with John Elkann and Benoît Ribadeau-Dumas’ valuable contribution to our Board. Exor’s continued presence on Institut Mérieux’s Board is a sign of our commitment to working closely together. Today, we welcome Exor’s increased direct stake in bioMérieux, which reflects our mutual confidence in the company’s strength, while its continued holding in Institut Mérieux reaffirms its support for